CTLA4 and prostate carcinoma: Moreover, MIT@ZIF-8 treatment increases the abundance of cytotoxic CD8<sup>+</sup> T cells and reduces the amount of immunosuppressive regulatory T cells in tumors, thereby enhancing anti-tumor immunity and sensitizing prostate cancer to anti-CTLA-4 immunotherapy.